Ramucirumab用于治疗肝癌

StephenW

Ramucirumab for liver cancer

Ramucirumab (Cyramza) led to improved overall survival and delayed disease progression in people with hepatocellular carcinoma (HCC), according to study results presented at the American Society of Clinical Oncology (ASCO) annual meeting last month in Chicago.

The REACH-2 study showed that second-line treatment with ramucirumab extended median survival by only about a month compared with placebo. However, the proportion of people who were still alive at 18 months after starting treatment more than doubled, from 11.3% to 24.5%.

Sorafenib (Nexavar) is the standard first-line systemic therapy for advanced HCC, according to recently updated HCC guidelines from the European Association for the Study of the Liver (EASL). The guidelines also recommend lenvatinib (Lenvima). Regorafenib (Stivarga) is recommended for second-line treatment, and cabozantinib (Cabometyx) has shown good results in clinical trials. Although EASL does not yet recommend immunotherapy for liver cancer, the US Food and Drug Administration has approved the checkpoint inhibitor nivolumab (Opdivo) for HCC.

Ramucirumab (Cyramza) is a monoclonal antibody that interferes with angiogenesis, or blood vessel formation. By blocking activation of vascular endothelial growth factor receptor 2 (VEGFR2), the drug prevents the development of new blood vessels needed to supply growing tumours.
Related links

    Read "Ramucirumab targeted therapy extends liver cancer survival" on infohep.org

StephenW

Ramucirumab用于治疗肝癌

根据上个月在芝加哥举行的美国临床肿瘤学会（ASCO）年会上的研究结果，Ramucirumab（Cyramza）导致肝细胞癌（HCC）患者的总体存活率和疾病进展延迟。

REACH-2研究显示，与安慰剂相比，ramucirumab的二线治疗仅使中位生存期延长了约一个月。然而，在开始治疗后18个月仍然活着的人的比例增加了一倍以上，从11.3％增加到24.5％。

根据最近更新的欧洲肝脏研究协会（EASL）的HCC指南，索拉非尼（Nexavar）是晚期HCC的标准一线全身治疗。该指南还建议使用lenvatinib（Lenvima）。 Regorafenib（Stivarga）推荐用于二线治疗，cabozantinib（Cabometyx）在临床试验中显示出良好的效果。尽管EASL尚未建议对肝癌进行免疫治疗，但美国食品和药物管理局已批准检测点抑制剂nivolumab（Opdivo）用于治疗HCC。

Ramucirumab（Cyramza）是一种干扰血管生成或血管形成的单克隆抗体。通过阻断血管内皮生长因子受体2（VEGFR2）的激活，该药物可防止供应生长肿瘤所需的新血管的发展。
相关链接

    阅读infohep.org上的“Ramucirumab靶向治疗延长肝癌生存期”